Healthcare Belgian Community
Our community narratives are driven by numbers and valuation.
Healthcare Belgian Investing Ideas
Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.
Agfa-Gevaert: A New Lease of Life Through Digitalisation and Materials Innovation A Careful Industrial Repositioning, Driven by Discipline, Digitalisation, and Speciality Materials Agfa-Gevaert (Euronext: AGFB) has undergone a transformation from an iconic photographic company into a focused digital imaging and specialty materials company. Following the sale of its Offset Solutions division to Aurelius Group in 2023, Agfa significantly reduced its exposure to the cyclical print sector and freed up capital for growth in higher-margin segments, such as digital radiology, industrial inkjet, and advanced chemical materials.Read more
APAC Expansion And Compounding Services Will Unlock Future Value
Key Takeaways Expansion into new regions and focus on personalized pharmaceuticals positions Fagron for future global growth as demand rises from aging populations and chronic conditions. Investment in automation, facility expansion, and quality strengthens operational efficiency and market leadership, paving the way for margin and earnings growth.Read more
FDA Approval And Expanding Network Will Grow US Sleep Market
Key Takeaways Recent regulatory approval and a distinctive product profile position Nyxoah for rapid growth and wider market penetration in the evolving sleep apnea landscape. Expanding clinical adoption, favorable reimbursement trends, and future indications support accelerating revenue, margin expansion, and scalable commercial success.Read more
Minimally Invasive Devices Will Capture Expanding Sleep Market
Key Takeaways Genio's unique features and focused U.S. rollout strategy could enable rapid market share gains, higher utilization, and sustained margin expansion. Nyxoah is positioned to benefit from global OSA diagnosis trends and expanding patient eligibility, driving long-term revenue growth above market expectations.Read more
Challenged Reimbursement And Cash Burn Will Test Neurostimulation Thesis Yet Long Term Potential Remains
Catalysts About Onward Medical Onward Medical develops and commercializes neurostimulation systems intended to improve function and quality of life for people with spinal cord injury. What are the underlying business or industry changes driving this perspective?Read more
Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery
Key Takeaways Regulatory, reimbursement, and administrative hurdles in the U.S. could restrict revenue growth, delay account expansion, and compress margins despite strong market demand. Innovation pressures, rising R&D costs, and increased competition threaten long-term profitability, market share, and Genio's premium product positioning.Read more
Clinic And Home Neuromodulation Adoption Will Drive Long Term Opportunity
Catalysts About Onward Medical Onward Medical develops neuromodulation therapies designed to restore function and improve quality of life for people with spinal cord injury and related conditions. What are the underlying business or industry changes driving this perspective?Read more
Proton Therapy Expansion Will Transform Global Cancer Treatment
Key Takeaways Sustained demand for advanced proton therapy and expansion into new markets are driving long-term revenue growth and improved earnings visibility. Continued R&D investments and growth in service contracts are enhancing margins, competitive positioning, and recurring high-margin revenue streams.Read more
